Table 1 Baseline characteristics and outcomes at baseline and 6-month follow-up

	Baseline			6-MFU			Baseline vs. 6-MFU
	n	M	SD	n	M	SD	p	effect size
NMSS total score	37	71.9	39.1	37	48.4	29.1	0.007	−0.34
Cardiovascular	37	1.6	2.7	37	1.1	2.5	0.238	−0.15
Sleep / fatigue	37	16.9	11.5	37	7.9	7.6	<0.001	−0.44
Mood / apathy	37	11.6	13.3	37	6.0	7.6	0.115	−0.21
Perceptual problems/ hallucinations	37	0.9	2.5	37	1.1	3.0	0.865	−0.03
Attention / memory	37	7.0	6.5	37	5.0	5.9	0.024	−0.29
Gastrointestinal	37	5.6	5.0	37	4.4	4.9	0.237	−0.16
Urinary	37	13.2	10.4	37	9.1	10.2	0.028	−0.28
Sexual function	37	3.8	5.0	37	3.0	4.3	0.313	−0.13
Miscellaneous	37	11.2	8.9	37	10.7	7.8	0.865	−0.02
PDQ-8 SI	37	32.3	14.8	37	22.6	14.1	<0.001	0.67
SCOPA-M total score	37	19.8	6.2	37	12.9	6.4	<0.001	−0.47
SCOPA-M-motor examination	37	9.4	4.2	37	6.7	4.1	0.008	−0.33
SCOPA-M-activities of daily living	37	6.6	2.7	37	4.1	3.1	0.003	−0.38
SCOPA-M-motor complications	37	3.8	2.3	37	2.1	2.4	<0.001	−0.44
LEDD [mg]	37	962.3	393.2	37	537.6	269.0	<0.001	1.2
LEDD DA [mg]	37	261.8	133.6	37	170.6	123.8	<0.001	0.7
AES	37	32.7	9.9	37	32.2	7.0	0.715	0.06

Demographic characteristics and outcome parameters at baseline and 6-months follow-up. Reported p values are corrected for multiple comparisons using Benjamini-Hochberg’s method. Bold font highlights significant results, p < 0.05.
6-MFU 6-month follow-up, AES Apathy Evaluation Scale, LEDD Levodopa equivalent daily dose, LEDD-DA LEDD of Dopamine Agonists, NMSS Non-Motor Symptom Scale, PDQ-8 SI 8-item Parkinson’s Disease Questionnaire summary index, SCOPA Scales for Outcomes in Parkinson’s disease.

Quick links

Search